NovoCure (NVCR) reported a quarterly loss of $0.23 per share for the period ending June 2022, compared to a Zacks Consensus Estimate of a loss of $0.14 and a loss of $0.14 per share in the same quarter last year. This resulted in an earnings surprise of -64.29%. The company’s revenue for the quarter was $140.87 million, exceeding expectations by 4.39% and representing a year-over-year increase from $133.52 million.
Over the past four quarters, NovoCure has only surpassed consensus EPS estimates once. The company’s shares have declined approximately 1.5% year-to-date, contrasted with a 15.6% drop in the S&P 500. For the upcoming quarter, the consensus EPS estimate stands at -$0.16 with projected revenues of $137.43 million, and the current fiscal year’s EPS estimate is -$0.55 on revenues of $550.11 million.
